Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment

Core Insights - Novo Nordisk has reported positive results from a Phase 3 trial of cagrilintide, a new weight-loss injection that operates differently from traditional GLP-1 inhibitors, leading to a gain in U.S.-listed shares [1][3]. Group 1: Trial Results - The Phase 3 trial of cagrilintide showed that patients lost an average of 12.5 kilograms (27.6 pounds), equating to an 11.8% reduction in body weight over 68 weeks, compared to a 2.5 kilograms (5.5 pounds) or 2.3% reduction with a placebo [2][5]. - Novo Nordisk plans to advance cagrilintide into a dedicated Phase 3 clinical program later this year due to the positive outcomes of the trial [3][5]. Group 2: Market Context - The company is exploring alternative weight-loss treatments as its existing drugs, Ozempic and Wegovy, have been losing market share to competitors [3]. - Despite a 2% gain in morning trading following the trial results, U.S.-listed shares of Novo Nordisk are down more than 30% year-to-date [3].